Analysts Offer Predictions for ADIL Q1 Earnings

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) – Equities researchers at Litchfield Hills Research issued their Q1 2026 earnings estimates for Adial Pharmaceuticals in a research note issued on Wednesday, September 24th. Litchfield Hills Research analyst T. O’neill expects that the company will post earnings per share of ($0.09) for the quarter. The consensus estimate for Adial Pharmaceuticals’ current full-year earnings is ($1.53) per share. Litchfield Hills Research also issued estimates for Adial Pharmaceuticals’ Q2 2026 earnings at ($0.09) EPS, Q3 2026 earnings at ($0.10) EPS and Q4 2026 earnings at ($0.10) EPS.

Adial Pharmaceuticals (NASDAQ:ADIL) last issued its earnings results on Wednesday, August 13th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.22) by $0.04.

A number of other equities research analysts also recently weighed in on the company. Zacks Research cut shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a research report on Saturday, July 26th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $8.00.

Adial Pharmaceuticals Stock Performance

NASDAQ:ADIL opened at $0.33 on Thursday. The firm’s 50-day simple moving average is $0.40 and its 200 day simple moving average is $0.52. Adial Pharmaceuticals has a 52 week low of $0.22 and a 52 week high of $1.30. The firm has a market cap of $7.31 million, a price-to-earnings ratio of -0.32 and a beta of 1.08.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Adial Pharmaceuticals stock. Citadel Advisors LLC lifted its holdings in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) by 63.8% during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 54,508 shares of the company’s stock after buying an additional 21,238 shares during the period. Citadel Advisors LLC owned approximately 0.85% of Adial Pharmaceuticals worth $55,000 at the end of the most recent reporting period. 16.41% of the stock is currently owned by institutional investors.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.